Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use

por Uitdehaag, Joost C. M., de Roos, Jeroen A. D. M., van Doornmalen, Antoon M., Prinsen, Martine B. W., de Man, Jos, Tanizawa, Yoshinori, Kawase, Yusuke, Yoshino, Kohichiro, Buijsman, Rogier C., Zaman, Guido J. R.
Publicado 2014

Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

por Uitdehaag, Joost C. M., de Roos, Jeroen A. D. M., van Doornmalen, Antoon M., Prinsen, Martine B. W., Spijkers-Hagelstein, Jill A. P., de Vetter, Judith R. F., de Man, Jos, Buijsman, Rogier C., Zaman, Guido J. R.
Publicado 2015

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

por Libouban, Marion A.A., de Roos, Jeroen A.D.M., Uitdehaag, Joost C.M., Willemsen-Seegers, Nicole, Mainardi, Sara, Dylus, Jelle, de Man, Jos, Tops, Bastiaan, Meijerink, Jules P.P., Storchová, Zuzana, Buijsman, Rogier C., Medema, René H., Zaman, Guido J.R.
Publicado 2017

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

por Kooijman, Jeffrey J., van Riel, Wilhelmina E., Dylus, Jelle, Prinsen, Martine B. W., Grobben, Yvonne, de Bitter, Tessa J. J., van Doornmalen, Antoon M., Melis, Janneke J. T. M., Uitdehaag, Joost C. M., Narumi, Yugo, Kawase, Yusuke, de Roos, Jeroen A. D. M., Willemsen-Seegers, Nicole, Zaman, Guido J. R.
Publicado 2022